Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP301 in dialysis patients with hyperphosphatemia
NCT06933472Phase 3Recruiting
- Sponsor
- Alebund Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of AP301 in hyperphosphatemia, sponsored by Alebund Pharmaceuticals. Started Jun 2025; status: recruiting.
02
Drugs
AP301
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06933472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933472.